logo
Dell wanted everyone back in the office 5 days a week. Employees say it's been open to interpretation.

Dell wanted everyone back in the office 5 days a week. Employees say it's been open to interpretation.

Yahoo2 days ago

Dell's companywide five-day RTO mandate started in March.
Managers have different interpretations of the rules, employees told BI.
The discrepancies in how it's enforced are causing "internal politics," one worker said.
After years of ramping up its RTO push, Dell called all its employees living near an office back to their desks full time starting March 3, saying it expected employees to do "a regular working day in the office" with "flexibility as needed."
Three months in, 10 Dell employees based in offices across the US have told BI that — in addition to challenges with RTO mandates like overcrowded offices and parking lots — the degree of enforcement so far has depended on the role and the manager. Some employees said they are in eight hours a day, while one employee described "badging" in and leaving soon after.
That's causing "lots of in-office politics," a Dell program manager said. They said they had worked from home for several days with "no problems" since March 3, while a teammate who did the same was "talked to." They said this fueled "gossip" about who is in eight hours a day and who isn't. The differing treatment was creating a "busy-body type environment" where "people on-site fight amongst each other based on who comes in and who doesn't," they added.
"So much of this is dependent on leaders," the program manager said, adding that it felt "haphazard."
A Dell spokesperson told BI the company's "expectations for our team members have not changed."
"They are expected to work a regular working day in the office, but have flexibility as needed," the spokesperson said. "Also, team members in global roles may need to take late evening calls and can adjust their in-office hours accordingly."
An internal FAQ obtained by BI, last updated on May 29, shared examples of when employees may be permitted to work from home, with approval from a leader. These included a temporary medical condition, needing to provide care on a temporary basis, or adjusting in-office hours to avoid peak traffic.
Of the five employees who told BI they sometimes worked from home, none said they were doing so for any of the reasons listed in the FAQ.
"I personally have not been adhering to eight hours a day," said one employee at company headquarters in Round Rock, Texas. "I am aware I may be breaking the rules, but no one has corrected me yet."
"My team is in the office five days a week, but I work about four hours and finish the day from home," said an employee in Oklahoma City.
An employee in tech support at Round Rock told BI they'd intentionally been coming in less since March 3 on "pure principle." They said they felt the new policy made them feel "treated like a child."
When the policy was announced in January, a Dell spokesperson told BI it would mean "more in-person connections to drive market leadership."
Vivek Mohindra, Dell's senior vice president of corporate strategy, previously told BI that having staff in the office brought "huge benefits," including "learning from each other, training, and mentorship."
The tech support worker said they come into the office for a few hours if there are in-person meetings. Otherwise, they're "just badging and then leaving," they said.
Others at Round Rock do the same, the employee said, adding they saw colleagues "do a little lap" and walk out to the parking lot — "less than five minutes in and out."
Some of the other employees BI spoke with said their managers were interpreting the mandate to mean five full days in the office.
Three said that since March 3, they had been expected to spend full days in the office. A fourth said their manager was initially flexible but was later asked to justify why some team members were not consistently in five days a week. The leader has to submit justification for employees to work away from the office and create an action plan for anyone falling short of the five days, they said.
Two other employees said the sales team, which has had a five-day RTO since September, had been particularly strict about enforcing a full working day.
When Dell announced the five-day RTO, it said flexibility in the workday would be agreed upon with managers. Continued noncompliance with the order "may result in disciplinary action," according to the FAQ BI obtained.
Three employees said they were unaware that a full day was the official requirement when asked by BI if they were in the office eight hours each day.
An April email from a senior executive, which BI has seen, seemed to capture the uncertainty around what was required.
James Christmas, the vice president of customer success, global services support, and deployment, informed some staff in the company's client solutions group to "maintain a consistent presence in the office, with a minimum of four hours daily."
A tech support worker who received the email told BI their team had been coming to the office for eight-hour days since early March, so the four-hour guidance surprised them. "I was told there was no WFH, and my manager was told the same thing," they added.
A Dell spokesperson declined to comment about Christmas' email.
pthompson@businessinsider.com
Read the original article on Business Insider

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025

Yahoo

time40 minutes ago

  • Yahoo

BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025

Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response: One complete response, three partial responses, and five stable diseases in nine evaluable patients so far Robust immune activation supporting clinical activity observed Study continues to enroll patients; dose optimization phase to follow. LUND, SE / / June 12, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated positive data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in cutaneous T-cell lymphoma (CTCL). The data will be presented in a poster at the European Hematology Association (EHA) 2025 congress, June 12-15 in Milan, Italy. As of the cut-off date May 15, 2025, data showed a 100% disease control rate in nine evaluable patients with CTCL. Forty-five percent of these patients achieved an objective response, with one patient achieving a complete response (CR), three achieving a partial response (PR), and five exhibiting stable disease (SD). Additionally, two patients with peripheral T-cell lymphoma (PTCL) were evaluable, of which one showed a PR, while the other showed SD. Overall, BI-1808 monotherapy demonstrates promising clinical activity and robust immune BI-1808 was well tolerated, with all treatment-related adverse events reported as mild or moderate (Grade 1-2). Notably, no Grade 3 or higher adverse events were observed. Transient disease flares, including skin peeling, erythema, and pruritus during the first weeks of treatment, were observed and shown to be associated with the BI-1808 immunologic mechanism. These flares coincide with regulatory T cell depletion and influx of CD8+ T cells into the skin, indicating on-target immune activation. Immunofluorescence multiplexing, starting at week 5, further confirmed increased CD8+ T cell infiltration and elevated granzyme B, supporting the drug candidate's mechanism of action. "These results reinforce the potential of BI-1808 as a novel immune-modulating therapy for CTCL," said Martin Welschof, Chief Executive Officer of BioInvent. "The early and sustained immune activation observed, combined with a favorable safety profile and 100% disease control rate, support the value of our anti-Tumor Necrosis Factor Receptor 2 (TNFR2) approach. We believe that these early Phase 2a data represent a meaningful milestone in our mission to deliver transformative therapies for difficult-to-treat patients, and we look forward to advancing BI-1808 into later-stage studies." Details of the poster:Title: Robust Single Agent Activity of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter, in Cutaneous T Cell Lymphoma (CTCL) PatientsSession Date and Time: June 13, 2025, 6:30-7:30 pm CESTSession Title: Poster Session 1Lead Author: Stefan K. Barta, University of Pennsylvania Hospital, Philadelphia, PA, USAAbstract Number: PF961 The poster will be posted to the Scientific Publications section of the company website ( ). The safety and preliminary efficacy of BI-1808 monotherapy are currently being evaluated in a sub-cohort (Part A) of the ongoing Phase 2a ( NCT04752826 ) study in patients with T-cell lymphomas, including CTCL. The study is expected to enroll 20 patients at a signal-seeking dose, after which a dose optimization phase is planned to be initiated. In April 2025, BioInvent received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BI-1808 for the treatment of CTCL and in March 2025, Orphan Drug Designation was received from the same agency for BI-1808 in T-cell lymphoma (TCL). About BI-1808The anti-TNFR2 antibody BI-1808 is part of BioInvent's tumor-associated regulatory T cells (Treg)-targeting program. TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy. BI-1808 is a first-in-class drug candidate in clinical development for the treatment of solid tumors and blood cancer. BI-1808 has shown single agent activity and excellent tolerability in an ongoing Phase 2a study and signs of efficacy and favorable safety profile in combination with pembrolizumab in the ongoing Phase 1/2a study. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at . For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-12 09:00 CEST. Attachments BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025 SOURCE: BioInvent International View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Major Company Giving Employees $1,000 LEGO Allowance
Major Company Giving Employees $1,000 LEGO Allowance

Yahoo

time4 hours ago

  • Yahoo

Major Company Giving Employees $1,000 LEGO Allowance

Companies will often give their employees perks and extra benefits. These can include discounts, free items and even vacations. One major company is offering a benefit to employees that has rarely been seen, but is sure to make those who work at other companies slightly jealous. Professional services firm Deloitte offers its employees an annual well-being subsidy of up to $1,000. Employees are allowed to use that subsidy on a variety of items, and recent guidelines have added "Legos and puzzles," according to Business Insider. The company has offered the subsidy for several years, and recently upped the amount from $500. It's offered to most partners and salaried workers at the company, but interns, contractors and those on a leave of absence aren't eligible. "Most of the responses are things like 'Lego?!?!? Finally!' or jokes about how they can now rationalize buying the coveted Millennium Falcon Star Wars Lego set," one employee told BI. Another employee was happy to see Legos added, and said that spending a few hours to build a set "is a great stress reliever." Many employees were reportedly happy that the company was thinking outside of the box when considering what employees could or would spend the subsidy on. The popular building bricks are just one of the new additions to the policy. Other items and categories added to the subsidy list this year include kitchenware and kitchen appliances, spa services, personal fans and ergonomic pillows. The subsidy is a great benefit for working at Deloitte, one of the biggest consulting firms in the world. The work is often demanding, with employees reporting that they work an average of 55 hours per week. "Since you are constantly changing projects and working with different leaders, achieving work-life balance is sadly always variable," one employee said while speaking to Women in Business. "Sometimes you get it, sometimes you really don't." Ernst & Young, another of the Big Four consulting and professional service firms, offers a similar subsidy that allows employees to purchase items like game consoles and mattresses. Deloitte had nearly 173,000 employees last year and generated over $33 billion in revenue. Major Company Giving Employees $1,000 LEGO Allowance first appeared on Men's Journal on Jun 12, 2025

Deloitte's US employees can now buy $1,000 of Lego on the company's dime to boost their well-being
Deloitte's US employees can now buy $1,000 of Lego on the company's dime to boost their well-being

Yahoo

time15 hours ago

  • Yahoo

Deloitte's US employees can now buy $1,000 of Lego on the company's dime to boost their well-being

Deloitte US offers its employees a $1,000 well-being subsidy to spend on things like gym memberships. The policy was updated in June to add several new items to the approved list, including Lego sets. "Lego?!?!? Finally!" was the reaction in internal chats, one Deloitte employee told Business Insider. Surviving the gruelling hours and high demands of a job in consulting isn't easy. Deloitte has a new solution to help its employees handle the stress: Lego. The Big Four professional services firm has updated its long-running well-being subsidy program to include "Legos and puzzles" on a list of items that Deloitte will reimburse, internal policy documents seen by Business Insider show. The firm has long offered eligible US staff an annual subsidy to spend on one or a combination of subscriptions, equipment, and experiences. In 2021, the firm doubled the allowance from $500 to $1,000, an internal webpage shows. The subsidy is meant to "empower and support your journey toward thriving mentally, physically, and financially and living your purpose," the policy documents say. Most partners and salaried workers are offered the benefit. Interns, contracted professionals, and employees on a leave of absence are not eligible. One Deloitte US employee told BI that people were discussing the new updates in internal team chats. "Most of the responses are things like 'Lego?!?!? Finally!' or jokes about how they can now rationalize buying the coveted Millennium Falcon Star Wars Lego set," the employee said. Lego's most expensive set, the Star Wars Ultimate Collector Series Millennium Falcon, costs $850, leaving Deloitte workers with a small allowance left over to spend on other qualifying items like fencing classes or neck pillows. A second Deloitte employee told BI that they see the subsidy as a nod of appreciation from the company for dealing with the stress and frustrations of their job. "This makes a huge difference! I personally like to think of what I need/want for the next subsidy. I have been able to upgrade my workspace, and it helps with the work intake," the person said. They added that Lego was receiving a lot of attention in the office, as it was a departure from the basics. "Knocking out a four-hour Lego build in under two hours is a great stress reliever," the employee said. Lego is just one of several new additions to the list of approved items, which were updated on June 1, the start of Deloitte's financial year. Under a section titled "what's new for FY26" are kitchenware and kitchen appliances (e.g., blender, refrigerator), spa services like facials and body treatments, personal portable cooling fans, and ergonomic, cooling, and sleeping pillows. Employees can also spend the subsidy on items like office furniture, gym equipment, financial support apps, fitness classes, and gaming consoles, including the Nintendo Switch and PlayStation. Deloitte US did not respond to a request for comment from BI. Not all are as positive about the subsidy program, with one Deloitte US employee telling BI they think it is only given "because of how much this job sucks." The US division of Deloitte has faced a challenging period after its contracts with the government came under scrutiny as part of the White House Office's efforts to cut federal spending. By April, at least 127 of the firm's government contracts had been cut or modified, according to BI's analysis of data on the DOGE website. That month, Deloitte Consulting CEO Jason Salzetti said in an internal meeting that a "small percentage" of workers in the firm's government division would be laid off. Employees told BI that DOGE's actions had shifted the climate at Deloitte. The US branch of Deloitte had 172,800 employees in 2024, when it last reported head count. Have a tip? Contact this reporter via email at pthompson@ or Signal at Polly_Thompson.89. Use a personal email address and a nonwork device; here's our guide to sharing information securely. Read the original article on Business Insider

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store